XM does not provide services to residents of the United States of America.

Indian shares end flat; fall in HDFC Bank offsets IT gains



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>INDIA STOCKS-Indian shares end flat; fall in HDFC Bank offsets IT gains</title></head><body>

Updates at close

By Bharath Rajeswaran and Hritam Mukherjee

BENGALURU, July 4 (Reuters) -Indian shares ended Thursday on a flat note as a drop in heavyweight HDFC Bank RIC offset gains across sectors, led by information technology stocks, on fresh hopes of a rate cut by the US Federal Reserve.

The NSE Nifty 50 .NSEI settled up 0.06% at 24,302.15 points, while the S&P BSE Sensex .BSESN added 0.08% to 80,049.67.

Both the benchmarks rose about 0.6% to hit record highs for the third session in a row on Thursday.

The broader, more domestically focussed small- .NIFSMCP100 and mid-caps .NIFMDCP100 rose about 0.5% each, outperforming the benchmarks.

Nine out of the 13 major sectors logged gains on the day.

Top private lender HDFC Bank HDBK.NS fell 2.35% after a three-session winning streak in which it rose about 5% on hopes of its weightage in the MSCI Emerging Markets index being increased

U.S. rate-sensitive IT stocks .NIFTYIT rose 1.1%. IT companies, which earn a significant share of their revenue from the U.S., stand to benefit from an early rate cut, according to analysts.

The gains in IT stocks comes after investors renewed their bets that the Federal Reserve could begin cutting rates in September following soft labour market data in the U.S.. GLOB/MKTS

Higher Fed rate makes emerging markets equities unattractive for foreign investors as elevated U.S. bond yields offer safety over riskier assets.

Pharma stocks .NIPHARM added 1.39%, and was the top sectoral percentage gainer, driven by Lupin LUPN.NS which ended about 8% higher after a Kotak double upgrade , citing robust earnings outlook.

Sun Pharma SUN.NS and Zydus Lifeciences ZYDU.NS rose 1.56% and 3.82%, respectively after getting tentative approvals from European and U.S. drug regulators for key drugs.

Third heaviest Nifty 50 stock - ICICI Bank ICBK.NS gained 2.61% on multiple block deals at a premium over last close.



Reporting by Hritam Mukherjee and Bharath Rajeswaran in Bengaluru; Editing by Mrigank Dhaniwala, Janane Venkatraman and Nivedita Bhattacharjee

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.